| 45th week of 2015 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20150313782 | LEG UP THERAPEUTIC LEG SUPPORT - A therapeutic device to support a persons leg, suitable for use with a chair or a bed, having a seat and extension and support means. The support means can be held in a horizontal position, or can be folded down, perpendicular to the seat, or it can be folding completely under the seat for storage. | 2015-11-05 |
| 20150313783 | Lifting Device for Disabled Person - The invention provides a lifting device ( | 2015-11-05 |
| 20150313784 | Lower Lumber Traction Device and Method of Use - A lower lumbar traction device for pulling and bending of the human spine with the hips suspended above the underlying surface. This device and method of use is a simple tool that when used properly may help those suffering from common forms of mechanically induced low back pain. The device and method of use uses gravity, leverage, and friction to produce decompressive forces directed at the most common location of discomfort, i.e., the posterior side of the lower lumbar vertebrae where bulging disc materials press against spinal nerves emerging from the spinal column as well as muscle stretching forces applied to lower and middle back area. The device comprises of: a width-adjustable and position-adjustable popliteal support mechanism; a popliteal support attachment mechanism; a truss with a plurality of slots; a hinge mechanism; a height-adjustable forward leg assembly with optional handles; a height-adjustable aft truss support mechanism; and a plurality of cables. | 2015-11-05 |
| 20150313785 | Therapeutic Spinal Traction Device - A therapeutic device for spinal traction has a modular assembly that allows an elongated base, a height-adjustable post, and a buttress to be used to adapt to individual preferences. The therapeutic device is designed to be easily adapted for use in a standing position or in a prone position. A head brace is connected by an extending member to an anchor, with multiple anchors being provided on the elongated base, the height-adjustable post, and potentially a projection member. The user places their head in the head brace and grasps the handle, pressing towards the buttress in order to create tension in the extending member and ultimately results in the creation of a targeted and isolated traction force. Thanks to the ease of assembly and adaption of the therapeutic device, it can be adjusted to fit personal characteristics of a wide range of persons. | 2015-11-05 |
| 20150313786 | WALKING ASSISTANCE DEVICE - A walking assistance device includes a waist wearing belt, a thigh link portion, a lower leg link portion, a lower leg wearing portion mounted on the lower leg link portion, a waist joint portion configured to hold an upper end portion of the thigh link portion so that the thigh link portion swings and the waist joint portion being mounted on the waist wearing belt, and a knee joint portion configured to connect the thigh link portion and the lower leg link portion so that the thigh link portion and the lower leg link portion swing. The thigh link portion and the lower leg link portion have rigidity that is greater in the front-rear direction and an up-down direction than in a right-left direction so as to be elastically twisted around an axis along an elongated direction. | 2015-11-05 |
| 20150313787 | Embedment Plate for Pedestrian Walkways with Reinforced Projections - An embedment tile for producing a tactilely detectable surface in a pedestrian walkway with an improved cross beam anchor. | 2015-11-05 |
| 20150313788 | METHOD AND DEVICE FOR THERAPEUTIC TREATMENT OF ILIOTIBIAL BAND SYNDROME, MYOFASCIAL AND MUSCULOSKELETAL DYSFUNCTIONS - A therapeutic treatment system that embodies a therapeutic method and a medical device for the treatment of Iliotibial Band Syndrome (ITBS), myofascial and/or musculoskeletal dysfunctions by utilizing negative pressure and suction to concurrently lift, lengthen, separate and stretch the iliotibial band to restore it to its correct functional length is provided. The medical device may include a suction implement coupled to an actuator handle, wherein the suction implement may be dimensioned and adapted to generate a negative pressure along a predetermined region requiring treatment. The user may operate the actuator handle so as to move it toward and away from the suction implement so that the suction implement is alternately deformed and returned to an undeformed condition, thereby alternately applying the negative pressure and suction to the predetermined region. | 2015-11-05 |
| 20150313789 | MUSCLE AND TISSUE THERAPY DEVICE - A massage therapy device having a roller and detachable thermal cover is disclosed. The roller has a series of unique ridges that optimize the application of therapeutic pressure to portions of a user's body. The thermal cover contains thermal retention material that can be heated or cooled. When the thermal cover is detachably connected to the roller, thermal therapy can be applied to muscle and other tissue in conjunction with the pressure therapy applied with the ridges of the roller. The configuration, temperature, and pressure application angle of the device can be varied to maximize the versatility of the device and provide individualized treatment. | 2015-11-05 |
| 20150313790 | MASSAGE MACHINE - A massage machine includes: a massage mechanism that includes a motor; a drive shaft configured to be driven and rotated by the motor; a pair of treatment members that include a pair of arms supported by the drive shaft and is moved closer to and further from each other by the rotation of the drive shaft; air cells which are provided on inner side surfaces of the arms, the air cells expand and contract in accordance with air supply and air discharge; and press treated portions arranged so as to face each other. The massage machine further includes an air unit that supplies and discharge air to and from the air cells and a control unit that controls the motor and the air unit. | 2015-11-05 |
| 20150313791 | Lay-on Vibrator - The invention relates to a lay-on vibrator having vibration means ( | 2015-11-05 |
| 20150313793 | MIRROR THERAPY DEVICE - A mirror therapy device includes a support unit, a camera unit and a display unit. The support unit has a control area adapted for supporting a normal hand of a patient thereon, and an image area disposed adjacent to the control area. The camera unit is disposed above the support unit, and includes a lens confronting the control area and adapted for capturing an image of the normal hand, and a processor coupled electrically to the lens for receiving the image thus captured and generating a mirror image mirroring the captured image. The display unit is disposed on the image area and is connected electrically to the processor for receiving and displaying the mirror image. | 2015-11-05 |
| 20150313794 | SYSTEM FOR PRODUCING A PACKAGED ITEM WITH AN IDENTIFIER - A system for packaging an item with an identifier comprises an identifier adder, a labeler, and a packager. The identifier adder adds one or more types of silica-based tags to an item, wherein each type of silica-based tag has a first signature readable using an optical spectroscopic reader. A label is generated based at least in part on reading the one or more types of silica-based tags of the item using the optical spectroscopic reader. The label includes goods info. The packager includes the label on a package, and wherein the packager includes the item in the package. | 2015-11-05 |
| 20150313795 | AUTOMATED FILLING SYSTEMS AND METHODS - Various embodiments of the present invention are directed to transferring fluidic media from a vial to a reservoir. In various embodiments, fluidic media may be transferred from the vial to the reservoir by moving a housing portion to move a plunger head located in the reservoir to draw fluidic media from the vial to the reservoir. In other embodiments, fluidic media may be transferred from the vial to the reservoir while the reservoir is held by a holding unit and vibrated by a vibrator to remove air from the fluidic media. In some embodiments, fluidic media may be transferred from the vial to the reservoir by moving a handle operatively connected to a bias member for assisting with the transfer of fluidic media. In other embodiments, the transfer of fluidic media may be assisted by a bias member and a needle connecting atmosphere and the vial. | 2015-11-05 |
| 20150313796 | System and Method for Mixing the Contents of Two Containers - In one aspect, the invention is directed to a port assembly for establishing fluid communication between a first container and a second container. The port assembly includes a retainer for connecting a first container, where the retainer is positioned in a cavity defined by a port housing that includes an axially fixed actuator. The housing also includes a plug member constructed to seal a fluid passageway between the port housing and an interior of a second container. The plug member is configured to move axially relative to the actuator. Rotation of the retainer relative to the actuator causes the plug member to move to an open position in which it does not seal a fluid passageway between the port housing and an interior of a second container. The rotation of the retainer relative to the port housing also causes the retainer to move axially relative to the port housing so that the actuator forces a stopper associated with a first container connected to the retainer into a first container. | 2015-11-05 |
| 20150313797 | CONNECTION DEVICE - In a connection device, when a cannula holding member is in a use state, a position of an end portion of an outer cylindrical portion on a retracted position side does not protrude to the retracted position side, with respect to a position of an end portion of an inner cylindrical portion on the retracted position side. Thereby, a connection device including a structure capable of holding a vial by holding means irrespective of the size of the vial can be provided. | 2015-11-05 |
| 20150313798 | ADAPTOR FOR REMOVAL OF FLUID FROM VIAL USING A NEEDLE-FREE SYRINGE - A needle-free adaptor for removing liquid from a vial comprises a cannula adapted to piece a septum of a vial, a plurality of legs surrounding the cannula to secure the adaptor to the vial when the cannula has pieced the septum, an elastomeric membrane having a normally closed pinhole orifice, and a conforming surface having an orifice connected to the cannula. The elastomeric membrane has a stable convex shape and is adapted to receive a nozzle of a needle-free device. Pressed against the elastomeric membrane, the nozzle deflects the elastomeric membrane from the convex shape to an unstable or pseudo-stable inverted position against the conforming surface. Buckling of the elastomeric membrane opens the pinhole orifice and enables fluid communication between the vial and the nozzle by interfacing the pinhole orifice with the orifice on the conforming surface. | 2015-11-05 |
| 20150313799 | REMINDER CAP - This disclosure relates to caps for containers, bottles and the like, and more particularly, to caps having reminder means to assist the user in remembering the next time a given activity is to be performed, such as the next time a dosage of medication should be taken. | 2015-11-05 |
| 20150313800 | ADHESIVE PREPARATION FOR MANDIBULAR PROSTHESES - A vegetable-based adhesive preparation for mandibular prostheses. The preparation has improved adhesive properties, consistency and stability as a result of a filler containing: 35 to 45 wt. % vegetable oil; 25 to 50 wt % structure-forming stabilizer; 5 to 15 wt % bonding agent; and silicon oxide making up the remainder. | 2015-11-05 |
| 20150313801 | DETECTION OF CARIOUS DENTIN TISSUE AND REMOVAL THEREOF BY MEANS OF A DENTAL INSTRUMENT - The application relates to a method for testing a dental instrument comprising the steps of: a) subjecting healthy dentin tissue free from smear layer(s) to treatment with a dental instrument, thereby yielding treated dentin tissue, b) addition of a composition comprising one or more hydrazine derivative(s) to the treated dentin tissue obtained in step a), c) examining if the treated dentin tissue in step b) is stained by the one or more hydrazine derivative(s), and d) determining whether or not the treated dentin tissue contains a smear layer, wherein said one or more hydrazine derivatives is a compound of formula (I) RNHNH | 2015-11-05 |
| 20150313802 | COMPOSITIONS FOR NEUTRALIZING AND COLORING HAIR AND METHODS THEREOF - The present invention relates to processes for neutralizing relaxed hair. Still further, the present invention relates to neutralizer compositions for use on relaxed hair. Still further, the present invention relates to a system for neutralizing relaxed hair. Yet further, the invention relates to relaxed hair neutralized by the compositions and methods disclosed herein. The present invention also relates to compositions and methods to simultaneously neutralize and color relaxed hair. | 2015-11-05 |
| 20150313803 | Consumer Products - A consumer product comprises: (a) a porous dissolvable solid structure, and (b) a hydrophobic coating comprising a benefit agent. The hydrophobic coating is applied to the porous dissolvable solid structure and the hydrophobic coating has a viscosity of less than 14.5 Pa·s. A method of forming an aqueous treatment liquor comprises the steps of: (a) providing a consumer product, (b) providing an aqueous solution, and (c) dissolving the consumer product in the aqueous solution to form an aqueous treatment liquor comprising a hydrophobic portion and an aqueous portion. The hydrophobic portion of the aqueous treatment liquor has a viscosity of less than about 14.5 Pa·s. | 2015-11-05 |
| 20150313804 | Consumer Products - A consumer product comprises: (a) a porous dissolvable solid structure, and (b) a hydrophobic coating comprising a benefit agent. The hydrophobic coating is applied to the porous dissolvable solid structure and the hydrophobic coating has an average thickness and/or maximum thickness of less than about 1000 microns. A method of forming an aqueous treatment liquor comprises the steps of: (a) providing a consumer product, (b) providing an aqueous solution, and (c) dissolving the consumer product in the aqueous solution to form an aqueous treatment liquor comprising a hydrophobic portion and an aqueous portion. | 2015-11-05 |
| 20150313805 | Consumer Products - A consumer product comprises: (a) a porous dissolvable solid structure, and (b) a hydrophobic coating comprising a benefit agent. The hydrophobic coating is applied to the porous dissolvable solid structure and the hydrophobic coating has an area density of application of less than about 250 μg per mm | 2015-11-05 |
| 20150313806 | Methods of Forming an Aqueous Treatment Liquor - A method of forming an aqueous treatment liquor comprising a benefit agent, the method comprising the steps of: (a) providing a consumer product comprising: (i) a porous dissolvable solid structure, and (ii) a hydrophobic coating comprising a benefit agent, the hydrophobic coating applied to the porous dissolvable solid structure, wherein the hydrophobic coating has a first viscosity; (b) providing an aqueous solution; and (c) dissolving the consumer product in the aqueous solution to form an aqueous treatment liquor comprising a hydrophobic portion and an aqueous portion, wherein the aqueous portion has a second viscosity. A ratio of the first viscosity of the hydrophobic coating to the second viscosity of the aqueous portion of the aqueous treatment liquor is less than about 100:1. | 2015-11-05 |
| 20150313807 | Methods of Forming an Aqueous Treatment Liquor - A method of forming an aqueous treatment liquor comprising a benefit agent, the method comprising the steps of: (a) providing a consumer product comprising: (i) a porous dissolvable solid structure, and (ii) a hydrophobic coating comprising a benefit agent, the hydrophobic coating applied to the porous dissolvable solid structure; (b) providing an aqueous solution; and (c) dissolving the consumer product in the aqueous solution to form an aqueous treatment liquor comprising a hydrophobic portion and an aqueous portion. The method provides a Capillary Number of less than about 1000. | 2015-11-05 |
| 20150313808 | Consumer Products - A consumer product comprises: (a) a porous dissolvable solid structure, (b) a first hydrophobic coating comprising a first benefit agent, and (c) a second hydrophobic coating comprising a second benefit agent. The first and second hydrophobic coatings are discretely applied to the porous dissolvable solid structure. A method of forming an aqueous treatment liquor comprises the steps of: (a) providing a consumer product, (b) providing an aqueous solution, and (c) dissolving the consumer product in the aqueous solution to form an aqueous treatment liquor comprising a hydrophobic portion and an aqueous portion. | 2015-11-05 |
| 20150313809 | Consumer Products - A consumer product comprises: (a) a porous dissolvable solid structure, and (b) a hydrophobic coating comprising a first benefit agent and a second benefit agent. The hydrophobic coating is applied to the porous dissolvable solid structure. The first benefit agent and the second benefit agent are premixed to form the hydrophobic coating before the hydrophobic coating is applied to the porous dissolvable solid structure. A method of forming an aqueous treatment liquor comprises the steps of: (a) providing a consumer product, (b) providing an aqueous solution, and (c) dissolving the consumer product in the aqueous solution to form an aqueous treatment liquor comprising a hydrophobic portion and an aqueous portion. | 2015-11-05 |
| 20150313810 | COSMETIC COMPOSITION IN THE FORM OF AN OIL-IN-WATER EMULSION - The present invention relates to a cosmetic composition, in the form of an oil-in-water emulsion, characterized in that it comprises a 2-acrylamido-2-methylpropanesulfonic acid polymer, a copolymer of 2-acrylamido-2-methylpropanesulfonic acid and of an alcohol(meth)acrylate, and a hydrophobic-modified inulin-based amphiphilic polymer, the globules of the said emulsion having a mean size ranging from 15 to 500 microns and the oily phase being present in an amount of less than 35% by weight relative to the total weight of the composition. The invention also relates to a cosmetic process for treating keratin materials. | 2015-11-05 |
| 20150313811 | RADIATION PROTECTION SYSTEM - The present invention relates to a shield for radiation attenuation. The shield includes a carrier suitable for topical application on human tissue, such as skin. The carrier includes an active ingredient that is homogenously dispersed throughout the carrier. The active ingredient includes an element suitable for attenuating radiation and having a high atomic number. | 2015-11-05 |
| 20150313812 | Matte Cosmetic Compositions - The present invention relates generally to cosmetic compositions that impart a matte finish to human integuments. More specifically, the invention relates to lip cosmetics that impart a matte finish. | 2015-11-05 |
| 20150313813 | Fluoride-Stable Zinc Containing Oral Care Compositions - Described herein are oral care compositions comprising a zinc ion source, a fluoride ion source, and a basic amino acid; along with methods of making and using the same. | 2015-11-05 |
| 20150313814 | COLORED LAMELLAR COMPOSITIONS - The present invention relates to a process for preparing a colored lamellar composition that may provide a wide range of colors. The process includes the steps of dispersing a colorant in a hydrocarbon, grinding the dispersed colorant to a particle size of less than about 1 micron (μm), and spraying the colorant onto a lamellar substrate to provide the colored lamellar composition while mixing and heating the lamellar composition to remove the hydrocarbon | 2015-11-05 |
| 20150313815 | EUTECTIC MIXTURES IN PERSONAL CARE COMPOSITIONS - The invention relates to active eutectic mixtures of butyl methoxydibenzoylmethane, isopropyl myristate and optionally 12-hydroxystearic acid, personal care products comprising such active eutectic mixtures, a method for preparing such personal care compositions and a method of applying to human skin such personal care compositions. | 2015-11-05 |
| 20150313816 | COMPOSITION COMPRISING A DICARBONYL COMPOUND AND AN ACID, THE PROCESS FOR STRAIGHTENING KERATIN FIBRES USING THIS COMPOSITION - The present invention relates to a cosmetic composition comprising: i) one or more dicarbonyl compounds corresponding to formula (I) below, and/or derivatives thereof and/or hydrates thereof and/or salts thereof: in which formula (I), R is as defined in the description, in a specific amount; ii) one or more acids different from the compound(s) i) as defined previously; and iii) one or more specific alkalinizing agents. The subject of the invention is also a process for straightening keratin fibres using ingredients i), ii) and iii) with a step of straightening by means of a straightening iron at a temperature of at least 150° C., preferably ranging from 150 to 250° C. | 2015-11-05 |
| 20150313817 | COMPOSITION OF MENTHOL AND MENTHYL LACTATE, ITS PREPARATION AND ITS USE AS A COOLING, FLAVOURING AND/OR FRAGRANCE AGENT - The present invention relates to a method of preparing liquid compositions essentially consisting of menthol and menthyl lactate and the use of such compositions as a cooling agent, flavouring agent and/or fragrance agent, products containing such compositions and methods of providing a physiological cooling effect by applying such compositions. | 2015-11-05 |
| 20150313818 | MATTE COSMETIC COMPOSITIONS - The present invention relates generally to cosmetic compositions that impart a matte finish to human integuments. More specifically, the invention relates to lip cosmetics that impart a matte finish. | 2015-11-05 |
| 20150313819 | Methods to Treat, Prevent, and Improve Skin Conditions - The present invention provides antagonists of acetylcholine receptors for the treatment of skin conditions. The present invention achieves treatment of skin conditions without causing the severe damage to the skin associated with antagonism of nicotinic acetylcholine receptors. | 2015-11-05 |
| 20150313820 | PREPARATIONS - Proposed are preparations, comprising special amides and menthol or menthol compounds or aromatic substances, characterized in that they have improved flavor and scent properties, and also that they allow the production of preparations, particularly emulsions with improved shelf life. | 2015-11-05 |
| 20150313821 | ANTIPERSPIRANT PRODUCTS WITH PROTEIN AND ANTIPERSPIRANT SALTS - The invention provides antiperspirant formulations comprising a protein and an antiperspirant salt in combination with a cosmetically acceptable carrier, together with methods of making and using these complexes and compositions. | 2015-11-05 |
| 20150313822 | ZINC AMINO ACID COMPLEX WITH CYSTEINE - Provided are compositions, e.g., oral and personal care products, comprising (i) a tetrabasic zinc-amino acid or trialkyl glycine-halide complex, and (ii) cysteine in free or in orally or cosmetically acceptable salt form, together with methods of making and using the same. | 2015-11-05 |
| 20150313823 | CATIONIC PYRITHIONE DISPERSION - The present invention provides a cationic dispersion containing pyrithione compound, water and a cationic surfactant. The cationic surfactant is present in an amount sufficient to disperse the pyrithione in water. The dispersion is useable as an additive to personal care compositions, such as conditioners. | 2015-11-05 |
| 20150313824 | SKIN CARE COMPOSITION - The invention relates to a topical composition that provides enhanced skin health by way of providing anti-aging benefits that are evident from visibly reduced wrinkles and under-eye dark circles. This is achieved through use of a synergistic combination of folic acid and gallated catechin in a specific weight ratio range. | 2015-11-05 |
| 20150313825 | METHODS AND COMPOSITIONS FOR LOCALLY INCREASING BODY FAT - Provided are methods for increasing fat locally in a body of a subject in need thereof comprising percutaneously administering to the subcutaneous fat of the subject a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, optionally delivered as a composition comprising a pharmaceutically acceptable carrier, as described herein. In certain embodiments, the pharmaceutically acceptable carrier comprises a percutaneous carrier, as described herein. Further provided are compositions comprising a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, for use according to the invention. | 2015-11-05 |
| 20150313826 | NAIL MAKEUP METHOD WITH PHOTOCROSSLINKABLE VARNISH COMPOSITIONS - The present invention relates to a makeup and/or care method of a nail and/or false nail, comprising a) applying a photocrosslinkable cosmetic composition (C1) onto a nail or false nail; b) exposing the coated nail or false nail obtained in step a) to UV or visible light radiation and then photocrosslinking to obtain a crosslinked layer (C′1); c) applying a photocrosslinkable cosmetic composition (C2) onto the nail or false nail coated with the crosslinked layer (C′1) obtained in step b); and d) exposing the coated nail or false nail to UV or visible light radiation and then photocrosslinking to obtain a crosslinked layer (C′2); the composition (C1) comprising in a physiologically acceptable medium at least one photocrosslinkable compound comprising at least two (meth)acrylate functions and at least one carboxylic acid function, at least one volatile solvent (S) in a proportion greater than or equal to 30% in relation to the total weight of the composition (C1), and at least one photoinitiator; the composition (C2) comprising, in a physiologically acceptable medium, 65 wt. % or more in relation to the total dry extract of (C2) of at least one photocrosslinkable urethane di(meth)acrylate compound, and at least one volatile solvent (S′). | 2015-11-05 |
| 20150313827 | PERSONAL CLEANSING COMPOSITIONS CONTAINING ZINC AMINO ACID/TRIMETHYLGLYCINE HALIDE - Provided is a personal cleansing composition for application to the skin which comprises a zinc X halide present in an amount to provide at least 0.36 weight % of the composition of zinc, and a surfactant, wherein X is an amino acid or trimethylglycine. Methods of making and using the compositions are also provided. The zinc X halide is can be used to deliver zinc salts to reduce or prevent sunburn, kill bacteria, or reduce perspiration. | 2015-11-05 |
| 20150313828 | METHOD OF DETANGLING HAIR - The method of facilitating detangling of hair described herein comprises applying to the hair a shampoo composition followed by a conditioner composition. The shampoo composition delivers consumer desired shampooing in addition preventing tangling of the hair. The shampoo and conditioner compositions can be applied to the hair and rinsed off with water. When used together, such as part of a hair care regimen, the shampoo and conditioner compositions combinations deliver improved detangling and combing of the hair in both the wet and dry state. | 2015-11-05 |
| 20150313829 | TOPICAL FORMULATIONS FOR THE PREVENTION AND TREATMENT OF ALOPECIA AND INHIBITION OF HAIR GROWTH - The present invention discloses formulations for the treatment and prevention of alopecia; the formulations comprise angiotensin-(1-7) and/or their analogues, encapsulated in ultradeformable vesicles prepared from specific combinations of phospholipids and surfactants, which confer efficacy to topical application in the control of hair growth, which indicates their great potential for the prevention and treatment of alopecia. The invention also describes formulations containing A779 Mas receptor antagonist of angiotensin-(1-7) and/or their analogues and their use in inhibiting hair growth. | 2015-11-05 |
| 20150313830 | Method And Compositions For Improving Selective Catabolysis And Viability In Cells Of Keratin Surfaces - A method for increasing cellular viability in cells of keratin surfaces after exposure to UV light and/or detoxifying cells of debris that impedes healthy metabolic function by topically applying to the keratin surface a composition containing at least one autophagy activator and at least one DNA repair enzyme and a method for making a topical composition comprising the steps of (a) identifying an ingredient that activates cellular autophagy in keratinocyte cultures in vitro, and (b) formulating the ingredient into a topical composition in combination with at least one DNA repair enzyme. | 2015-11-05 |
| 20150313831 | NAIL COMPOSITIONS - The invention relates to nail composition sets comprising at least one primer, at least one bonding composition, and at least one color coat, wherein the primer comprises water and at least one adhesive compound and preferably further comprises at least one water-soluble film forming agent and/or at least one plasticizer. | 2015-11-05 |
| 20150313832 | METHOD OF REDUCING FRIZZ AND IMPROVING MOISTURIZATION - The method of reducing frizz of hair described herein comprises applying to the hair a shampoo composition followed by a conditioner composition. The shampoo composition delivers consumer desired shampooing and conditioning while also delivering frizz reduction to the hair. The shampoo and conditioner compositions can be applied to the hair and rinsed off with water. When used together, such as part of a hair care regimen, the shampoo and conditioner compositions combinations deliver improved fizz reduction, and in the moisture seeking group, also delivers moisturized hair feel. | 2015-11-05 |
| 20150313833 | METHOD OF DELIVERING SMOOTH FEEL TO HAIR - The method of delivering a smooth hair feel described herein comprises applying to the hair a shampoo composition followed by a conditioner composition. The shampoo composition delivers consumer desired shampooing in addition to providing a smooth feel of the hair. The shampoo and conditioner compositions can be applied to the hair and rinsed off with water. When used together, such as part of a hair care regimen, the shampoo and conditioner compositions combinations deliver smooth feel of the hair. | 2015-11-05 |
| 20150313834 | METHOD OF REPAIRING AND PREVENTING HAIR DAMAGE - The method of facilitating repairing and preventing damage of hair described herein comprises applying to the hair a shampoo composition followed by a conditioner composition. The shampoo composition delivers consumer desired shampooing in addition repairing and preventing damage of the hair. The shampoo and conditioner compositions can be applied to the hair and rinsed off with water. When used together, such as part of a hair care regimen, the shampoo and conditioner compositions combinations deliver hair damage repair and prevention. | 2015-11-05 |
| 20150313835 | COMPOSITIONS INCLUDING A BOTANICAL EXTRACT AND METHODS OF USING THE SAME IN SKIN WHITENING AND SKIN LIGHTENING APPLICATIONS - Compositions for topical use and having a melanin synthesis-inhibiting activity that include an amount of a botanical extract of at least one of | 2015-11-05 |
| 20150313836 | Dry Pharmaceutical Compositions for Topical Delivery of Oral Medications, Nasal Delivery and to Treat Ear Disorders - In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent. | 2015-11-05 |
| 20150313837 | POLYMERIC HYDROGEL COMPOSITIONS WHICH RELEASE ACTIVE AGENTS IN RESPONSE TO ELECTRICAL STIMULUS - A polymeric hydrogel composition is described for the delivery of a pharmaceutically active agent when an electrical stimulus is applied to the composition. The composition comprises a polymer which forms the hydrogel, such as poly vinyl alcohol (PVA) cross-linked with diethyl acetamidomalonate (DAA), an electroactive polymer such as polyaniline and a pharmaceutically active agent such as an analgesic, and in particular, indomethacin. The composition can be subcutaneously implanted at a targeted site and under normal conditions, the active agent will be entrapped in the hydrogel itself. However, upon the application of an electric current to the hydrogel, the active agent will be released. When the electric current is removed, the change is reversed and the active agent will cease to be released. In one embodiment of the invention, the hydrogel composition is for use in alleviating chronic pain. | 2015-11-05 |
| 20150313838 | Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders - Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 2015-11-05 |
| 20150313839 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS - Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 2015-11-05 |
| 20150313840 | CHEWABLE SOFT CAPSULES - A matrix formulation for a soft chewable capsule is provided which includes a gel-forming composition, a plasticizer, a polymer modifier, and water. The polymer modifier may be a carboxylic acid or other organic compound that alters the physical and/or chemical properties of the capsule formulation. A chewable soft capsule is also provided, having enhanced organo-leptic and processing properties. An active material may be delivered to a user using this dosage form. A method of forming the chewable soft capsule is also provided. | 2015-11-05 |
| 20150313841 | COMBINATION OF UMECLIDINIUM, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE FOR USE IN THE TREATMENT OF INFLAMMATORY OR RESPIRATORY TRACT DISEASES - The present invention is directed to pharmaceutical combination products comprising a muscarinic acetylcholine receptor antagonist, fluticasone propionate and salmeterol xinafoate, and to their use in the treatment of inflammatory or respiratory tract diseases. | 2015-11-05 |
| 20150313842 | UNIT DOSES, AEROSOLS, KITS, AND METHODS FOR TREATING HEART CONDITIONS BY PULMONARY ADMINISTRATION - Methods of treating atrial arrhythmia include administering an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof, such that the at least one antiarrhythmic pharmaceutical agent first enters the heart through the pulmonary vein to the left atrium. Other methods of treating atrial arrhythmia include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. An amount of the at least one antiarrhythmic pharmaceutical agent may peak in the coronary sinus of the heart at a time ranging from 10 seconds to 30 minutes from initiation of the administering. Unit doses, aerosols, and kits are also contemplated. | 2015-11-05 |
| 20150313843 | SOLID GANAXOLONE COMPOSITIONS AND METHODS FOR THE MAKING AND USE THEREOF - In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm. | 2015-11-05 |
| 20150313844 | MICROPARTICLES COMPRISING A PROBIOTIC, CROSS-LINKABLE REAGENT, A DENATURED PROTEIN, POLYOL PLASTICISER AND TREHALOSE - The present invention relates to microparticles, methods of producing microparticles and microparticle precursor compositions. In particular, it relates to microparticles comprising a protective matrix and a protective matrix precursor composition comprising a blend of a denatured protein, a polyol plasticizer, trehalose and a carrier. | 2015-11-05 |
| 20150313846 | PROLONGED-RELEASE MULTIMICROPARTICULATE ORAL PHARMACEUTICAL FORM - Modified-release multimicroparticulate pharmaceutical form capable of maintaining the modified release of the active principle in an alcoholic solution and of resisting attempts at misuse. | 2015-11-05 |
| 20150313847 | Compressed Tablets - The present invention pertains to a method of producing a compressed tablet in a rotary tablet press. The method including the steps of adding a first powdered portion of tablet base material into a punch die of a rotary tablet press, pressing the first tablet base material by means of an upper and a lower punch to obtain a first pressed material, inserting an object at the upper face of the first pressed material and fixing the object in a central cavity of the first pressed material, adding a second powdered portion of tablet base material into the punch die of the rotary tablet press, and pressing the first and second tablet base material around the object to enclose the object from the surface of the tablet. The object is based on a material different from the first and/or the second powdered portion of tablet base material. | 2015-11-05 |
| 20150313848 | PHARMACEUTICAL COMPOSITIONS OF RIFAXIMIN - The present invention relates to stable pharmaceutical compositions comprising rifaximin and processes for their pre-paration. | 2015-11-05 |
| 20150313849 | Methods of Treatment of Attention Deficit Hyperactivity Disorder - Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 7 hours or longer, followed by an ascending release rate. When administered at night the composition provides early morning improvement in symptoms of ADHD and sustained improvement over a period of at least 12 hours. | 2015-11-05 |
| 20150313850 | CONTROLLED RELEASE FORMULATIONS HAVING RAPID ONSET AND RAPID DECLINE OF EFFECTIVE PLASMA DRUG CONCENTRATIONS - The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval. | 2015-11-05 |
| 20150313851 | COMPOSITION FOR THE TRANSDERMAL DELIVERY OF FENTANYL - A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl. | 2015-11-05 |
| 20150313852 | ANIMAL FEED COMPOSITIONS AND FEEDING METHODS - This invention relates to animal feed compositions. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of increasing and optimizing feed efficiency in animals. | 2015-11-05 |
| 20150313853 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF - The present invention relates to the technical field of chemically synthesized drugs, in particular to an anti-HIV drug or prodrug and preparation method and uses thereof. The compound or prodrug compound of the present invention has a structural formula as represented by formula I. The compounds have anti-HIV-1 and anti-HIV-2 virus activity, and have a C8166 therapeutic index as high as 2081.59 and an H9 therapeutic index as high as 303.03. Furthermore, the compounds have high solubility up to 1290-2845.5 μg/ml in an aqueous solution, and can be formulated into an oral formulation. | 2015-11-05 |
| 20150313854 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE - The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist. | 2015-11-05 |
| 20150313855 | EFFERVESCENT COMPOSITIONS CONTAINING N-ACETYLCYSTEINE - Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described. | 2015-11-05 |
| 20150313856 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I.1, Formula I.2, Formula IA, Formula IB, Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfex, busulfan, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin and chlorambucil. | 2015-11-05 |
| 20150313857 | Novel Formulation of Naproxen - The present invention relates to methods for producing particles of naproxen using dry milling processes as well as compositions comprising naproxen, medicaments produced using naproxen in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of naproxen administered by way of said medicaments. | 2015-11-05 |
| 20150313858 | DIALYSIS COMPOSITION - The present invention relates to an acid concentrate dialysis composition an acid concentrate dialysis composition comprising a mixture of citric acid and citrate, having pH of less than 3.0, wherein the total concentration of citrate is between 35 mM and 450 mM, and wherein the amount of citric acid is more than 50% of the total concentration of citrate. The acid concentrate dialysis composition is to be combined to form a dialysis solution having a total concentration of citrate of between 1 and 6 mM. | 2015-11-05 |
| 20150313859 | METHODS AND COMPOSTIONS FOR TREATMENT OF CANCER - The invention discloses a method of treating cancer refractory to an anticancer agent comprising administering to a cancer patient a pharmaceutical composition comprising at least one compound of Formula 1 | 2015-11-05 |
| 20150313860 | METHODS OF REDUCING MILK SOMATIC CELL COUNT - Provided are methods of reducing milk somatic cell count using L-arginine supplementation of lactating ruminant animals during gestation, and/or during the lactation phase post parturition to decrease somatic cell count in milk produced by the animals. | 2015-11-05 |
| 20150313861 | EICOSAPENTAENOIC ACID-PRODUCING MICROORGANISMS, FATTY ACID COMPOSITIONS, AND METHODS OF MAKING AND USES THEREOF - The present invention is directed to isolated microorganisms as well as strains and mutants thereof, biomasses, microbial oils, compositions, and cultures; methods of producing the microbial oils, biomasses, and mutants; and methods of using the isolated microorganisms, biomasses, and microbial oils. | 2015-11-05 |
| 20150313862 | "Pharmaceutical composition for reducing the trimethylamine N-oxide level" - The invention discloses the use of pharmaceutical compositions containing 3-(2,2,2-trimethylhydrazinium)propionate dihydrate and pharmaceutically acceptable salts thereof for trimethylamine N-oxide level decrease in a body. | 2015-11-05 |
| 20150313863 | Composition and Method for Treating Neuronal Ceroid Lipofuscinosis - Provided herein are methods for treatment of a neurodegenerative disease, such as neuronal ceroid lipofuscinosis including administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent that mediates upregulation of TPP 1. | 2015-11-05 |
| 20150313864 | Fe(III) Complex Compounds for the Treatment and Prophylaxis of Iron Deficiency Symptoms and Iron Deficiency Anemias - The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias. | 2015-11-05 |
| 20150313865 | ANHYDROUS AND HEMIHYDRATE CRYSTALLINE FORMS OF AN (R)-BACLOFEN PRODRUG, METHODS OF SYNTHESIS AND METHODS OF USE - Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed. | 2015-11-05 |
| 20150313866 | BREAST CANCER THERAPY BASED ON HORMONE RECEPTOR STATUS WITH NANOPARTICLES COMPRISING TAXANE - The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention relates to the use of nanoparticles comprising paclitaxel and albumin (such as Abraxane®) either alone or in combination with other chemotherapeutic agents or radiation, which may be used for the treatment of breast cancer which does not express estrogen receptor and/or progesterone receptor. | 2015-11-05 |
| 20150313867 | ANTI-TUMOURAL EFFECTS OF CANNABINOID COMBINATIONS - The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). | 2015-11-05 |
| 20150313868 | USE OF CANNABINOIDS AND TERPENES FOR TREATMENT OF ORGANOPHOSPHATE AND CARBAMATE TOXICITY - Pharmaceutical compositions in which isolated cannabinoid receptor modulators are optionally combined with terpene blends in a pharmaceutically acceptable carrier. Methods for treating or preventing a disease, disorder, dysfunction or condition caused by exposure to an organophosphate or carbamate acetylcholineesterase inhibitor with the inventive compositions are also disclosed. | 2015-11-05 |
| 20150313869 | FLAVONOID HYDROGEL - There is provided methods for producing a hydrogel comprising conjugates of a hydrogel forming agent and a flavonoid including a method for producing a hydrogel that is capable of adhesion of cells and which comprises enzymatically cross-linked conjugates of a hydrogel forming agent and a flavonoid. There is also provided a method for producing a hydrogel comprising conjugates of a hydrogel forming agent and a flavonoid without the addition of an exogenous peroxide or peroxidase or without the addition of an exogenous peroxide. Hydrogels produced by such methods and methods of using the hydrogels are also described herein. | 2015-11-05 |
| 20150313870 | LOW DOSE TOPIRAMATE / PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF - A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate. | 2015-11-05 |
| 20150313871 | Methods of Treating Portal Hypertension - The present invention provides methods for treating or preventing portal hypertension comprising administering to a patient in need of such treatment or prevention at least one Rev-erb modulating agent (REMA) in an amount effective to treat or prevent said portal hypertension. The REMA can be SR6452 or a related compound, such as SR9009 or SR9011. The amount of the REMA administered can comprises a quantity sufficient to modulate Rev-erbα expression, activity, and/or subcellular location and/or to inhibit or reverse hepatic stellate cell (HSC) activation and contractility. | 2015-11-05 |
| 20150313872 | COMBINATION OF A SLOW SODIUM CURRENT BLOCKER AND A SINUS IF CURRENT INHIBITOR, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMBINATION - The present invention relates to the combination of a selective late sodium current blocker and a selective, specific sinus If current inhibitor, and to the pharmaceutical compositions containing said combination. | 2015-11-05 |
| 20150313873 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof - Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/β-catenin signaling pathway, and serve to reduce β-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents. | 2015-11-05 |
| 20150313874 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS - Hydrazone compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein. | 2015-11-05 |
| 20150313875 | SALINOSPORAMIDES AND METHODS OF USE THEREOF - The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet | 2015-11-05 |
| 20150313876 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA - The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs, and prodrugs thereof. The methods and the compositions can be used for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania). | 2015-11-05 |
| 20150313877 | TREATMENT OF ADHD - A method is described for treating attention deficit hyperactivity disorder (ADHD), by administering to the individual an anti-epileptic mood stabiliser at a dose which is sub-therapeutic for mood stabilisation, optionally in combination with a psychostimulant. Also described is a method of improving reading comprehension and/or fluency in an individual suffering from learning difficulties which method comprises administering to the individual an anti-epileptic mood stabiliser. | 2015-11-05 |
| 20150313878 | METHODS FOR DIAGNOSING AND TREATING PROSTATE CANCER - The invention is directed to a method of inhibiting prostate cancer cell proliferation using a substance that inhibits the activity of a soluble adenylyl cyclase (sAC) protein. The invention also is directed to methods of diagnosing and prognosticating prostate cancer in a subject by evaluating sAC gene or protein expression in the subject. | 2015-11-05 |
| 20150313879 | Synergistic Microbicidal Combinations - Antimicrobial compositions based on the synergistic combination of 2-methyl-3-isothiazolone and selected commercial microbicides where the compositions are substantially free of halogenated 3-isothiazolone, are disclosed. Particularly preferred are combinations of 2-methyl-3-isothiazolone together with benzoic acid, citric acid, sorbic acid, 1,2-dibromo-2,4-dicyanobutane, 1,3-dimethylol-5,5-dimethylhydantoin, phenoxyethanol, benzyl alcohol, zinc pyrithione or climbazole, that provide enhanced microbicidal efficacy at a combined active ingredient level lower than that of the combined individual 3-isothiazolone and commercial microbicide effective use levels. | 2015-11-05 |
| 20150313880 | Synergistic Microbicidal Combinations - Antimicrobial compositions based on the synergistic combination of 2-methyl-3-isothiazolone and selected commercial microbicides where the compositions are substantially free of halogenated 3-isothiazolone, are disclosed. Particularly preferred are combinations of 2-methyl-3-isothiazolone together with benzoic acid, citric acid, sorbic acid, 1,2-dibromo-2,4-dicyanobutane, 1,3-dimethylol-5,5-dimethylhydantoin, phenoxyethanol, benzyl alcohol, zinc pyrithione or climbazole, that provide enhanced microbicidal efficacy at a combined active ingredient level lower than that of the combined individual 3-isothiazolone and commercial microbicide effective use levels. | 2015-11-05 |
| 20150313881 | Therapeutic Methods for Type I Diabetes - The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds. | 2015-11-05 |
| 20150313882 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER - The present invention is related to a compound of formula (I) a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of cancer, wherein X is selected from the group consisting of N—R | 2015-11-05 |
| 20150313883 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS - Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine compound) or to another pharmaceutically acceptable salt form. | 2015-11-05 |
